Tirzepatide is a dual agonist developed by Eli Lilly: it acts on both the GLP-1 and the GIP receptor, two gut-hormone receptors involved in appetite, insulin release and energy balance. It is approved in the United States for type 2 diabetes (Mounjaro) and for chronic weight management (Zepbound), and its weight trials are the phase 3 SURMOUNT programme, summarised below with the side effects they reported.
Weight Loss · Compound File
Tirzepatide for weight loss
Tirzepatide is a dual GLP-1 and GIP receptor agonist and the active ingredient in Mounjaro and Zepbound. This page covers what its phase 3 SURMOUNT trials measured, the side effects they reported, and what happened when treatment stopped.
Video transcript
Searched compounded tirzepatide in the Philippines? Three different things are sold under that name. One molecule, a dual GIP and GLP-1 agonist. What differs is who makes it, and whether it is registered. Compounding means a pharmacy prepares a medicine for a prescription, instead of a manufacturer producing a registered product. Two Philippine telehealth programs name it: GoRocky and &you. &you states its tirzepatide is compounded by a licensed pharmacy and is not FDA-approved. In the Philippines, tirzepatide is registered only as Mounjaro, with 12 certificates of product registration. Compounded tirzepatide has none. Same molecule as Mounjaro, but not the same product: a compounded version has not been through registration. Prescribing belongs with a licensed Philippine physician. FDA Philippines has warned against unregistered tirzepatide products 3 times, in July and September 2026. Three routes, then. The registered pen, on prescription. Compounding, on prescription through a program. And the research vial: not a medicine, not approved for human use, research only. Our partner and supplier, Primara Labs, lists a 15 mg tirzepatide vial at ₱1,890, or ₱1,155 in a 10 pack. Per mg, the 15 mg KwikPen at Watsons, 4 doses for ₱29,900, is about ₱498. The vial: ₱126, or ₱77 in a 10 pack. Not the same product. Every order includes bacteriostatic water, insulin syringes and alcohol pads. Same day in Metro Manila when ordered by noon on a weekday, J&T to the provinces. Pay by GCash, Maya or InstaPay. 60-day money-back guarantee: if an accredited independent lab reports the vial is not the compound on the label, Primara refunds what you paid. Read the full guide on Philippines Peptides, then see tirzepatide at Primara Labs and order on WhatsApp.
- SURMOUNT-1 mean weight lossPhase 3, 15 mg arm, against 3.1% on placebo
- 20.9%
- SURMOUNT-1 duration
- 72wk
- Class
- GLP-1 + GIP
- US FDA
- Approved
Overview
What the SURMOUNT trials found
In SURMOUNT-1, a 72-week phase 3 trial of 2,539 adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes, body weight fell by 15%, 19.5% and 20.9% on the 5 mg, 10 mg and 15 mg arms, against 3.1% on placebo. Source
Every SURMOUNT trial on file, with its population and comparator, is on the tirzepatide guide.
Our partner and supplier lists tirzepatide 15mg at PHP 2,100, or PHP 1,890 with the standing 10% off, as a research vial. Buy tirzepatide in the Philippines
Side effects reported
SURMOUNT-1, a 72-week phase 3 trial of 2,539 adults with BMI of 30 or more, or 27 or more with at least one weight-related complication, excluding diabetes, reported: Discontinuation for adverse events: 4.3%, 7.1% and 6.2% on the 5, 10 and 15 mg arms, against 2.6% on placebo. Source
SURMOUNT-3, a 72-week phase 3 trial of 579 adults with BMI of 30 or more, or 27 or more with at least one obesity-related complication (excluding diabetes), who achieved 5.0% or more weight reduction after a 12-week intensive lifestyle intervention, reported these adverse events against placebo:
- Discontinuation for adverse events: 10.5% on the Maximum tolerated dose (10 or 15 mg) arm, against 2.1% on placebo.
- Nausea: 39.7% on the Maximum tolerated dose (10 or 15 mg) arm, against 14% on placebo.
- Diarrhoea: 31% on the Maximum tolerated dose (10 or 15 mg) arm, against 9.2% on placebo.
- Constipation: 23% on the Maximum tolerated dose (10 or 15 mg) arm, against 6.8% on placebo.
- Vomiting: 18.1% on the Maximum tolerated dose (10 or 15 mg) arm, against 1.4% on placebo.
The product labels also carry warnings for pancreatitis, gallbladder disease and thyroid C-cell tumours, the last seen in rodent studies. The GLP-1 side effects guide covers them in full.
Mounjaro and Zepbound
Tirzepatide is the active ingredient in both Mounjaro and Zepbound. Registration, availability and dated pharmacy prices in the Philippines are on the Mounjaro page and the Zepbound page.
Mounjaro is a prescription medicine in the Philippines, and prescribing belongs with a licensed Philippine physician. Whether it suits you, and at what dose, is a decision for that physician. The tirzepatide guide covers what the trials of tirzepatide measured and the side effects they reported. What Philippine law says about registration and prescriptions is in the regulation hub.
After stopping
What happens when treatment stops was measured in SURMOUNT-4, an 88-week phase 3 trial in which adults who completed a 36-week lead-in on tirzepatide were randomised to continue or switch to placebo: from week 36 to week 88, body weight fell by 5.5% on continued treatment and rose by 14% after the switch to placebo. Source
↗ Related guides